HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 801–900 of 1,008
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors
Serrano, C., George, S., Valverde, C. M., Olivares, D., García‐Valverde, A., Suárez, C., Morales‐Barrera, R., & Carles, J. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0490-9 · Cited by 46
Jana, N. K., & Nanda, S. (2018) · New Journal of Chemistry · doi:10.1039/c8nj02534g · Cited by 46
Extracellular Heat Shock Protein-90 (eHsp90): Everything You Need to Know
Jay, D. G., Luo, Y., & Li, W. (2022) · Biomolecules · doi:10.3390/biom12070911 · Cited by 48
Petersen, A. L. D. O. A., Guedes, C. E. S., Versoza, C. L., Lima, J. G. B., de Freitas, L. A. R., Borges, V. M., & Veras, P. S. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049496 · Cited by 50
“Some of these client proteins are known to be key oncogenic proteins that are upregulated in cancer cells [11,13,14].”
BackgroundA novel HSP90 chaperone complex regulates intracellular vesicle transport
Lotz, G. P., Brychzy, A., Heinz, S., & Obermann, W. M. J. (2008) · Journal of Cell Science · doi:10.1242/jcs.015610 · Cited by 45
“The dependence of oncogenic kinases on HSP90 and its vulnerability to drugs have made HSP90 a promising target for cancer therapy (Kamal et al., 2003; Whitesell and Lindquist, 2005).”
BackgroundHeat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias
Bansal, H., Bansal, S., Rao, M. K., Foley, K. P., Sang, J., Proia, D. A., Blackman, R. K., Ying, W., Barsoum, J., Baer, M. R., et al. (2010) · Blood · doi:10.1182/blood-2009-10-247239 · Cited by 52
Heat shock protein expression in canine malignant mammary tumours
Romanucci, M., Marinelli, A., Sarli, G., & della Salda, L. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-171 · Cited by 52
“The need for valid in vivo models for further testing Hsp90-targeted cancer therapy, currently under clinical trial with promising early results [22,51-53], also appears to be essential, as a recent study has highlighted a potential contraindication to this therapy, since the Hsp90 inhibitor, 17allylamino-17-demothoxy…”
BackgroundHDAC Inhibitors and Chaperone Function
Rao, R., Fiskus, W. C., Ganguly, S., Kambhampati, S., & Bhalla, K. N. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00007-0 · Cited by 47
Ohba, S., Hirose, Y., Yoshida, K., Yazaki, T., & Kawase, T. (2009) · Journal of neurosurgery · doi:10.3171/2009.3.jns081146 · Cited by 50
Mei, H., Wu, H., Yang, J. C., Zhou, B., Wang, A., Hu, C., Qi, S., Jiang, Z., Zou, F., Wang, B., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01240-3 · Cited by 45
“CHIP is one of the key players of the protein quality control system and mediates the poly-ubiquitination of misfolded or aggregated proteins for targeted degradation.(50,51) We next investigated whether the CHIP E3 ubiquitin ligase played an essential role underlying the mechanism of IHMT-337-induced EZH2 ubiquitinat…”
BackgroundNCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer
Liu, J., Su, Y., Zhang, C., Dong, H., Yu, R., Yang, X., Tian, Y., Feng, Y., Zhang, J., Shi, M., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114579 · Cited by 46
Haupt, A., Joberty, G., Bantscheff, M., Fröhlich, H., Stehr, H., Schweiger, M. R., Fischer, A., Kerick, M., Boerno, S. T., Dahl, A., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-38 · Cited by 47
“Constitutive kinase activity of the unstable truncated mutant requires a stronger association, rendering it more susceptible to Hsp90 inhibition [1].”
BackgroundInfluentialMatokanović, M., Barišić, K., Filipović‐Grčić, J., & Maysinger, D. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.001 · Cited by 46
“As an inhibitor of Hsp90, celastrol has been extensively studied, because inhibition of this single protein can cause degradation of multiple oncoproteins (Whitesell and Lindquist, 2005).”
BackgroundA CHIPotle in physiology and disease
Paul, I., & Ghosh, M. K. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.10.027 · Cited by 47
Wider, D., Gulli, M., Briand, P.-A., Tatu, U. S., & Picard, D. (2009) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2008.12.011 · Cited by 48
“Because Hsp90 has been recognized as an Achilles heel of cancer cells, there are already a considerable number of drugs available andmore are beingdeveloped, and clinical trials are currently being conductedwith GA derivatives [2,8,9].”
BackgroundRichardson, J. B., Uppendahl, L. D., Traficante, M. K., Levy, S. F., & Siegal, M. L. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003733 · Cited by 48
“It has been proposed that understanding robustness is crucial for understanding healthy and diseased states [3–5], as well as the potential for populations to adapt to evolutionary pressures [6,7].”
UVR Exposure Sensitizes Keratinocytes to DNA Adduct Formation
Nair, S. V., Kekatpure, V. D., Judson, B. L., Rifkind, A. B., Granstein, R. D., Boyle, J. O., Subbaramaiah, K., Guttenplan, J. B., & Dannenberg, A. J. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0125 · Cited by 45
“Inhibitors of Hsp90 suppress levels of multiple client proteins including the AhR (33, 42).”
BackgroundCdc37 Interacts with the Glycine-Rich Loop of Hsp90 Client Kinases
Terasawa, K., Yoshimatsu, K., Iemura, S.-I., Natsume, T., Tanaka, K., & Minami, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.9.3378-3389.2006 · Cited by 46
“series of Cdc37 deletion mutants [especially Cdc37(1-200) and”
BackgroundMethodInfluentialKim, S., Bajji, A. C., Tangallapally, R. P., Markovitz, B., Trovato, R., Shenderovich, M. D., Baichwal, V. R., Bartel, P. L., Cimbora, D. M., McKinnon, R. S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3004619 · Cited by 48
Lee, S.-C., Min, H., Choi, H., Kim, H. S., Kim, K.-C., Park, S., Seong, M. A., Seo, J. H., Park, H., Suh, Y., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096883 · Cited by 45
“In general, Hsp90 inhibitors interfere with the binding of ATP to the nucleotide-binding pocket of Hsp90 in the N- or C-terminal domains (Whitesell and Lindquist, 2005).”
BackgroundInfluentialPhysiological functions of Wilms’ tumor 1‐associating protein and its role in tumourigenesis
Xie, W., Wei, L., Guo, J., Guo, H., Song, X., & Sheng, X. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28402 · Cited by 49
“WTAP forms a complex with molecular chaperone Hsp90, which has been shown to keep the stability of various tumor‐promoting oncoproteins, including WT1, and the binding of them is dependent on WTAP activity.(15,56,57) Further investigation has found that treatment of Hsp90 inhibitor ganetespib leads to the degradation…”
BackgroundZheng, D.-W., Liu, W., Xie, W., Huang, G., Jiang, Q., Yang, Y., Huang, J.-R., Xing, Z., Yuan, M.-L., Wei, M.-N., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00387-1 · Cited by 45
“Heat-shock protein 90 (Hsp90), a molecular chaperone, is essential for eukaryotic cell survival and has been highly conserved during evolution.(7) Hsp90 consists of three domains, namely the N, middle, and C domain,(8) and regulates the balance of stabilization, activation, and degradation of client proteins, includin…”
BackgroundJanz, M., Stühmer, T., Vassilev, L. T., & Bargou, R. C. (2007) · Leukemia · doi:10.1038/sj.leu.2404565 · Cited by 45
Naito, Y., Nishida, T., & Doi, T. (2023) · Gastric Cancer · doi:10.1007/s10120-023-01381-6 · Cited by 44
Landmann, H., Proia, D. A., He, S., Ogawa, L. S., Krämer, F., Beißbarth, T., Grade, M., Gaedcke, J., Ghadimi, M. B., Moll, U. M., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.378 · Cited by 46
“Geldanamycin-based compounds represented the mainstay of HSP90 inhibition for the last 20 years.(8) Clinically, however, these compounds proved to be of limited value due to their inherent liver and ocular toxicity coupled with only modest potency in vivo.”
BackgroundPeng, C., Li, D., & Li, S. (2007) · Cell Cycle · doi:10.4161/cc.6.18.4722 · Cited by 44
Haider, K., & Huggins, D. J. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci4003409 · Cited by 44
Eichner, S., Knobloch, T., Floss, H. G., Fohrer, J., Harmrolfs, K., Hermane, J., Schulz, A., Sasse, F., Spiteller, P., Taft, F., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201106249 · Cited by 44
Kaiser, M., Lamottke, B., Mieth, M., Jensen, M. R., Quadt, C., García-Echeverría, C., Atadja, P. W., Heider, U., von Metzler, I., Türkmen, S., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01403.x · Cited by 44
“4 del13q14, t(11;14) Mel, Bor, Len Not reached 14”
BackgroundTargeted therapies in breast cancer
Rojo, F., Albanell, J., Rovira, A., Corominas, J. M., & Manzarbeitia, F. (2008) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2008.08.001 · Cited by 44
Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG)
Chandran, T., Katragadda, U., Teng, Q., & Tan, C. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.056 · Cited by 45
“…is responsible for conformational maturation nd stability of a myriad of signaling proteins, including HER2, BCRBL, estrogen receptors, androgen receptors, insulin-like growth actor 1 receptor, hypoxia-inducible factor 1 , B-Raf, cdk4 and kt among numerous others (Whitesell and Lindquist, 2005).”
BackgroundSamanta, A. K., Chakraborty, S. N., Wang, Y., Schlette, E. J., Reddy, E. P., & Arlinghaus, R. B. (2010) · Genes & Cancer · doi:10.1177/1947601910372232 · Cited by 49
“HSP90 is overexpressed in leukemia and also in many other cancers, and it is assumed that in cancer, the requirement of HSP90 is critical since most of the client proteins of HSP90s are active participants in signal transduction pathways of cancer cells.(33,36-38) These qualities and functional aspects of HSP90 make i…”
BackgroundEdwards, J. A., Zemska, O., & Rappleye, C. A. (2011) · Infection and Immunity · doi:10.1128/iai.05124-11 · Cited by 44
“types ranging from cancer to antifungal drug resistance (6, 39).”
BackgroundWhen Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
Shah, S. P., Lonial, S., & Boise, L. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0135 · Cited by 49
“Numerous other reports have been published regarding HSP90 inhibitors (32, 38, 39).”
Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors
Byrd, K. M., Subramanian, C., Sanchez, J., Motiwala, H. F., Liu, W., Cohen, M. S., Holzbeierlein, J. M., & Blagg, B. S. J. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201504955 · Cited by 44
Liu, Q., Tu, G., Hu, Y., Jiang, Q., Liu, J., Lin, S., Yu, Z., Li, G., Wu, X., Tang, Y., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114013 · Cited by 45
The complex dance of the molecular chaperone Hsp90
Neckers, L., Mollapour, M., & Tsutsumi, S. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.01.006 · Cited by 45
Ocaña, A., & Pandiella, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1630 · Cited by 47
Pham, L., Christadore, L. M., Schaus, S. E., & Kolaczyk, E. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100891108 · Cited by 44
Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2
Tanaka, K., Eskin, A., Chareyre, F., Jessen, W. J., Manent, J., Niwa‐Kawakita, M., Chen, R., White, C., Vitte, J., Jaffer, Z. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3167 · Cited by 44
“HSP90 is a ubiquitous molecular chaperone that is responsible for maintaining a subset of proteins involved in cell proliferation and transformation (18).”
BackgroundATP-Dependent Lon Protease Contributes to Helicobacter pylori-Induced Gastric Carcinogenesis
Luo, B., Wang, M., Hou, N., Hu, X., Jia, G., Qin, X., Zuo, X., Liu, Y., Luo, K., Song, W., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.03.001 · Cited by 44
Chen, F., Tang, C., Yang, F., Ekpenyong, A., Qin, R., Xie, J., Momen‐Heravi, F., Saba, N. F., & Teng, Y. (2024) · Science Advances · doi:10.1126/sciadv.adk3663 · Cited by 51
Dong, J., Ma, F., Cai, M., Cao, F., Li, H., Liang, H., Li, Y., Ding, G., Li, J., Cheng, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01518 · Cited by 47
Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways
Morceau, F., Chateauvieux, S., Orsini, M., Trécul, A., Dicato, M. A., & Diederich, M. F. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.03.013 · Cited by 46
Synthetic Lethal Vulnerabilities of Cancer
de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 51
Floris, G., Dêbiec‐Rychter, M., Woźniak, A., Stefan, C., Normant, E., Faa, G., Machiels, K., Vanleeuw, U., Sciot, R., & Schöffski, P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0148 · Cited by 43
“Heat shock protein 90 (HSP90) is one of the most abundant proteins in a cell (9).”
BackgroundActivity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
Wu, X., Marmarelis, M. E., & Hodi, F. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056134 · Cited by 45
“Inhibition of HSP90 results in increased degradation of client proteins via the ubiquitin proteasome pathway [2].”
BackgroundInfluentialChiappori, F., Merelli, I., Milanesi, L., Colombo, G., & Morra, G. (2016) · Scientific Reports · doi:10.1038/srep23474 · Cited by 43
Targeting protein quality control pathways in breast cancer
Sannino, S., & Brodsky, J. L. (2017) · BMC Biology · doi:10.1186/s12915-017-0449-4 · Cited by 44
Dai, J., Chen, A., Zhu, M., Qi, X., Tang, W., Liu, M., Li, D., Gu, Q., & Li, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.012 · Cited by 45
An updated patent review of anticancer Hsp90 inhibitors (2013-present)
Li, L., Chen, N., You, Q., & Xu, X. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1829595 · Cited by 44
Cui, H., Kapur, M., Diedrich, J. K., Yates, J. R., Ackerman, S. L., & SCHIMMEL, P. R. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1183 · Cited by 45
“a heat shock-like response (57)), proteasome inhibition with MG132 (which impairs degradation of ubiquitinated proteins (58)), and mTORC-1 inhibition by Torin-1 (59), did not lead to differences in puromycin labelling between wildtype and LZ cells (Figure 4E, Supplementary Figure S2D).”
BackgroundPU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction
Trendowski, M. R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.007 · Cited by 46
Pechenino, A. S., & Frick, K. M. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.09.017 · Cited by 47
Reddy, N. M., Voorhees, P. M., Houk, B. E., Brega, N. M., Hinson, J. M., & Jillela, A. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.010 · Cited by 46
Inhibition of HSP90 with Pochoximes: SAR and Structure‐Based Insights
Barluenga, S., Fontaine, J., Wang, C., Aouadi, K., Chen, R., Beebe, K. E., Neckers, L., & Winssinger, N. (2009) · ChemBioChem · doi:10.1002/cbic.200900494 · Cited by 47
Okoye, F. B. C., Lu, S., Nworu, C. S., Esimone, C. O., Proksch, P., Chadli, A., & Debbab, A. (2013) · Tetrahedron Letters · doi:10.1016/j.tetlet.2013.05.117 · Cited by 43
González‐Romero, R., Rivera-Casas, C., Frehlick, L. J., Méndez, J., Ausió, J., & Eirin-Lopez, J. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030006 · Cited by 41
“The suitability of this DNA fragment was further assessed by high nucleosome occupancy scores (as revealed by computational analyses using the NuPoP software, see Materials and Methods), including a p53 binding site encompassing potential applications for future genotoxicity tests in aquaculture industry as well as in…”
MethodProteomic identification of tumor biomarkers associated with primary gallbladder cancer
Huang, H.-L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5511 · Cited by 43
Correlation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancer
Gao, J., Song, B., Peng, J.-J., & Lu, Y.-M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i41.5965 · Cited by 47
Liu, H.-J., Jiang, X., Guo, Y., Sun, F., Kou, X., Bao, Y., Zhang, Z., Lin, Z., Ding, T., Jiang, L., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.9 · Cited by 44
Fan, W., Gao, X. K., Rao, X. S., Shi, Y. P., Liu, X. C., Wang, F. Y., Liu, Y. F., Cong, X. X., He, M. Y., Xu, S. B., et al. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00211-18 · Cited by 45
“lated in response to heat to facilitate protein folding or degradation (51).”
BackgroundHsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation
Pan, C., Chun, J., Li, D., Boese, A. C., Li, J., Kang, J., Umano, A. D., Jiang, Y., Song, L., Magliocca, K. R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125963 · Cited by 45
Wang, L., Jiang, J., Zhang, L., Zhang, Q., Zhou, J., Li, L., Xu, X., & You, Q. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01659 · Cited by 37
Kulka, L. A. M., Fangmann, P.-V., Panfilova, D., & Olzscha, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00425 · Cited by 44
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs)
Qiu, Y., Li, X., He, X., Pu, J., Zhang, J., & Lu, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112764 · Cited by 45
Wolf, S., Sohmen, B., Hellenkamp, B., Thurn, J., Stock, G., & Hugel, T. (2021) · Chemical Science · doi:10.1039/d0sc06134d · Cited by 44
Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches
Sumi, M. P., & Ghosh, A. (2022) · Cells · doi:10.3390/cells11060976 · Cited by 46
“Since Hsp90 was identified as a potential cancer target, various inhibitors targeting cytoplasmic Hsp90 have been established as anticancer agents [73,142,143], and many different inhibitors with desirable pharmacological properties, including ganetespib (STA-9090), have been evaluated in clinical trials, but none hav…”
BackgroundRecent advances toward the development of Hsp90 C-terminal inhibitors
Amatya, E., & Blagg, B. S. J. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129111 · Cited by 49
Organelle-specific Hsp90 inhibitors
Seo, Y. H. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0636-1 · Cited by 42
Adwan, T. S., Ohm, A. M., Jones, D. N. M., Humphries, M. J., & Reyland, M. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.255950 · Cited by 45
Liu, S.-H., Lin, C., Liang, F.-P., Chen, P., Kuo, C., Alam, M. M., Maiti, B., Hung, S., Chi, C., Sun, C., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.014 · Cited by 42
“Since Hsp90 has been reported to regulate the stability of v-Src and v-Src-induced cell transformation [1,41], we next determined whether Hsp90 cleavage was a key event in the andrographolidemediated decrease in v-Src and the resulting biological effects.”
BackgroundInfluentialLou, J., Fatima, N., Xiao, Z., Stauffer, S., Smythers, G. W., Greenwald, P., & Ali, I. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0216 · Cited by 43
“level of another member of the molecular chaperone family, Hsp90 (35), in HCT-116 cells, but had no effect on Hsp90 in HCA-7 cells.”
BackgroundInfluentialKim, H.-B., Lee, S.-H., Um, J., Kim, M., Hyun, S.-K., Gong, E. J., Oh, W. K., Kang, C., & Kim, S. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10896 · Cited by 42
“In addition, Hsp90 has an approximately 100-fold greater affinity for its inhibitors in cancer cells than in normal cells due to multi-chaperone complexes of Hsp90 in an activated, high-affinity conformation, enabling selective targeting of Hsp90 of cancer cells [8, 9].”
BackgroundHeat shock proteins as targets in oncology
Órtiz, A. G., & Salcedo, J. M. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0486-8 · Cited by 43
“The Hsp90 function as a chaperone is to assure the correct conformation, activity, localisation and turnover with proteolysis of a wide number of proteins, some of them involved in cell growth, differentiation and survival [ 11 ].”
BackgroundSuda, A., Kawasaki, K., Komiyama, S., Isshiki, Y., Yoon, D.-O., Kim, S., Na, Y.-J., Hasegawa, K., Fukami, T. A., Sato, S., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.036 · Cited by 41
Cottin, D., Shillito, B., Chertemps, T., Tanguy, A., Léger, N., & Ravaux, J. (2010) · Marine Genomics · doi:10.1016/j.margen.2010.05.002 · Cited by 41
“Functionally, HSP90 proteins are known to play roles in steroid receptor formation, protein folding, protein degradation and regulation of signal transduction pathways (Zhao and Houry, 2005; Whitesell and Lindquist, 2005).”
BackgroundLiu, W., Vielhauer, G. A., Holzbeierlein, J. M., Zhao, H., Ghosh, S., Brown, D. R., Lee, E., & Blagg, B. S. J. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097303 · Cited by 41
“A number of Hsp90 inhibitors that target the N-terminal ATP-binding pocket have demonstrated potent antiproliferative effects (Roe et al., 1999; Whitesell and Lindquist, 2005; Avila et al., 2006); however, a major drawback associated with their use is that they induce a prosurvival heatshock response (HSR), which resu…”
BackgroundMartínez‐Bussenius, C., Navarro, C. A., Orellana, L. H., Paradela, A., & Jerez, C. A. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.03.039 · Cited by 43
Chen, Y., Chang, C.-W., Tsay, Y., Huang, L.-Y., Wu, Y.-C., Cheng, L.-H., Yang, C.-C., Wu, C., Teo, W., Hung, K.-F., et al. (2018) · Theranostics · doi:10.7150/thno.25784 · Cited by 44
“Molecular chaperones and co-chaperones play critical roles in maintaining substrate protein homeostasis through control of the folding, stability, and function of many proteins also known as “client proteins” [3, 4].”
BackgroundWang, Y., 王荣泽, Li, F., Wang, Y., Zhang, Z., Wang, Q., Ren, Z., Jin, F., Kitazato, K., & Wang, Y. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0066-x · Cited by 44
Pemigatinib, a Potent Inhibitor of FGFRs for the Treatment of Cholangiocarcinoma
Merz, V., Zecchetto, C., & Melisi, D. (2020) · Future Oncology · doi:10.2217/fon-2020-0726 · Cited by 41
An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
Sun, Y., Yue, L., Xu, P., & Hu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.927587 · Cited by 43
“Frontiers in Oncology 08 stabilizing proteins (91, 92).”
BackgroundHsp90 modulates CAG repeat instability in human cells
Mittelman, D., Sykoudis, K., Hersh, M., Lin, Y., & Wilson, J. H. (2010) · Cell Stress and Chaperones · doi:10.1007/s12192-010-0191-0 · Cited by 40
“Hsp90 is highly expressed in tumor cells, suggesting that the buffering and stabilizing functions of Hsp90 may also be vital to the survival and proliferation of malignant cells (Whitesell and Lindquist 2005).”
BackgroundLi, Y., Shan, G., Peng, Z., Zhu, J. H., Meng, S., Zhang, T., Gao, L., Tao, P., Gao, R., Li, Y., et al. (2010) · Antiviral chemistry & chemotherapy · doi:10.3851/imp1631 · Cited by 41
“Previous studies have focused primarily on the stabilization of tumour cell oncogenic proteins by HSP90 [1,2].”
BackgroundIsoflavone-deprived soy peptide suppresses mammary tumorigenesis by inducing apoptosis
Park, K., Choi, K., Kim, H., Kim, K., Lee, M. H., Lee, J.-H., & Rim, J. C. K. (2009) · Experimental & Molecular Medicine · doi:10.3858/emm.2009.41.6.042 · Cited by 41
ATP Binding to Hsp90 Is Sufficient for Effective Chaperoning of p53 Protein
Walerych, D., Gutkowska, M., Klejman, M. P., Wawrzynow, B., Tracz, Z., Wiech, M., Zylicz, M., & Zylicz, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.112110 · Cited by 40
Taguwa, S., Kambara, H., Omori, H., Tani, H., Abe, T., Mori, Y., Suzuki, T., Yoshimori, T., Moriishi, K., & Matsuura, Y. (2009) · Journal of Virology · doi:10.1128/jvi.01035-09 · Cited by 41
“receptors and cell-signaling kinases (66).”
Li, W., Miao, X., Qi, Z., Zeng, W., Liang, J., & Liang, Z. (2010) · Virology Journal · doi:10.1186/1743-422x-7-45 · Cited by 41
Li, C., Huang, W., Wu, J.-M., Yu, S.-C., Hu, T., Uen, Y., Tian, Y.-F., Lin, C.-N., Lu, D. Y., Fang, F.-M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1369 · Cited by 44
Lai, K.-H., Liu, Y., Su, J.-H., El‐Shazly, M., Wu, C., Du, Y.-C., Hsu, Y., Yang, J., Weng, M.-K., Chou, C., et al. (2016) · Scientific Reports · doi:10.1038/srep36170 · Cited by 41
Metabolic control of antifungal drug resistance
Robbins, N., Collins, C., Morhayim, J., & Cowen, L. E. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.07.004 · Cited by 40
Mellatyar, H., Akbarzadeh, A., Rahmati, M., Ghalhar, M. G., Etemadi, A., Nejati‐Koshki, K., Zarghami, N., & Barkhordari, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.20.8693 · Cited by 40
“Heat shock proteins (HSPs) are chaperones which have considerable expression in tissues that are exposed to proteotoxic stressors (such as elevated temperatures, heavy metals, hypoxia and acidosis) (Whitesell and Lindquist, 2005; Makhnevych and Houry, 2012; Mestril et al., 2014).”
BackgroundRay-Coquard, I., Braicu, I., Berger, R., Mahner, S., Sehouli, J., Pujade-Lauraine, E., Cassier, P. A., Moll, U. M., Ulmer, H., Leunen, K., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00832 · Cited by 37
“Due to their aberrant conformation mutp53 proteins depend on permanent folding support by Hsp90, a cancer-induced multi-component chaperone machinery from the heat shock family (13).”
Background“Reinforcement” by Tumor Microenvironment: The Seventh “R” of Radiobiology
Taghizadeh‐Hesary, F. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.09.027 · Cited by 48
Blacklock, K. M., & Verkhivker, G. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071936 · Cited by 40
Mechanisms of Disease: the role of heat-shock protein 90 in genitourinary malignancy
Lattouf, J., Srinivasan, R., Pinto, P. A., Linehan, W. M., & Neckers, L. Μ. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0604 · Cited by 44
“These facts, considered together, point towards a possible protective role of heat-shock proteins in neoplastic processes”
BackgroundThermoregulation in the life cycle of nematodes
Devaney, E. (2006) · International Journal for Parasitology · doi:10.1016/j.ijpara.2006.02.006 · Cited by 41
Kaufmann, S. H., Karp, J. E., Litzow, M. R., Mesa, R. A., Hogan, W. J., Steensma, D. P., Flatten, K. S., Loegering, D. A., Schneider, P. A., Peterson, K. L., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049551 · Cited by 40
“This client protein down-regulation raises the possibility that Hsp90 inhibitors such as tanespimycin and alvespimycin might be used to target multiple potential resistance mechanisms simultaneously.(1,3,6) In addition, tanespimycin selectively inhibits growth of aneuploid cells.”
BackgroundChallenges in identifying cancer genes by analysis of exome sequencing data
Hofree, M., Carter, H. K., Kreisberg, J. F., Bandyopadhyay, S., Mischel, P. S., Friend, S. H., & Ideker, T. (2016) · Nature Communications · doi:10.1038/ncomms12096 · Cited by 46
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.